Psychiatric Adverse Events Associated with Varenicline: An Intensive Postmarketing Prospective Cohort Study in New Zealand
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background Psychiatric adverse events, including depression, suicidal ideation and psychotic reactions have been reported in patients taking the smoking cessation medicine varenicline. However, data regarding the frequency of psychiatric adverse reactions in 'real-life' postmarketing use are limited to date.Objective The aim of the study was to calculate the occurrence rates of psychiatric adverse reactions in a nationwide general population prescribed varenicline in New Zealand.Methods Observational prospective cohort study using Prescription Event Monitoring methods. All New Zealand patients dispensed a prescription for varenicline from 1 April 2007 to 31 March 2008 were included in this study. Patients were followed up by multiple methods, including linkage to national morbidity and mortality datasets, questionnaires to patients' doctors and assessment of spontaneous reports sent to the Intensive Medicines Monitoring Programme. Main outcome measures were occurrence rates of psychiatric adverse events in the total patient cohort and in the subgroup for whom a follow-up questionnaire was returned (the 'responder population').Results The cohort for this study included 3415 patients prescribed varenicline during the first year of monitoring in New Zealand. Follow-up by record linkage was performed for 3353 (98%) patients, and questionnaires were returned for 1394 (42%) of these patients. Of 1394 questionnaires returned, 1310 were valid and defined as the 'responder' population. Sleep disorders, including insomnia, sleep disturbance, dreams and nightmares, were the most frequently reported psychiatric events and were experienced by 56 (4.3%) patients in the responder population. Symptoms of depression were reported by 39 (2.98%) patients in the responder population (24 new-onset depression, 14 worsening of pre-existing depression and 1 report of impaired motivation). Withdrawal reactions after stopping varenicline were reported by 6 (0.46%) patients in the responder population. Serious psychiatric reactions including suicide (one case), suicidal ideation (two cases) and psychotic reactions (three cases) were also identified. Six self-harm events (one fatal, five non-fatal) were identified in the total cohort, giving an occurrence rate of 0.18% (95% CI 0.06, 0.38) in this population.Conclusions This intensive postmarketing study of 3415 New Zealand patients demonstrates that psychiatric adverse events are commonly reported in patients taking varenicline. Approximately 3% of patients experienced symptoms of depression and the majority of these cases appeared to have a causal association with varenicline. Serious psychiatric reactions including suicide, suicidal ideation and psychotic reactions were also identified, but these were less frequently reported.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They found that sleep disorders were the most frequently reported psychiatric events with an N of 56 (4.3%) patients in the responder population.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [47]
In the citing paper
“Six self-harm events (one fatal, five non-fatal) were identified in the total cohort, giving an occurrence rate of 0.18% (95% CI: 0.06, 0.38) in this population.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [47]
In the citing paper
“Serious psychiatric reactions including suicide (one case), suicidal ideation (two cases), and psychotic reactions (three cases) were also identified.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [47]
In the citing paper
“Symptoms of depression were reported by 39 (2.98%) patients (24 new-onset depression, 14 worsening of pre-existing depression, and 1 report of impaired motivation).”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [47]
Citations
Cites
Primary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions
Fischer, M. A., Stedman, M. R., Lii, J., Vogeli, C., Shrank, W. H., Brookhart, M. A., & Weissman, J. S. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1253-9 · Cited by 572
Harmonisation in Pharmacovigilance
Edwards, I. R., & Biriell, C. (1994) · Drug Safety · doi:10.2165/00002018-199410020-00001 · Cited by 395
Rigotti, N. A., Pipe, A. L., Benowitz, N. L., Arteaga, C., Garza, D., & Tonstad, S. (2010) · Circulation · doi:10.1161/circulationaha.109.869008 · Cited by 369
Adverse Drug Reactions: A Critical Review
Karch, F. E. (1975) · JAMA · doi:10.1001/jama.1975.03260250028021 · Cited by 335
Gunnell, D., Irvine, D., Wise, L., Davies, C., & Martin, R. M. (2009) · BMJ · doi:10.1136/bmj.b3805 · Cited by 200
Tonstad, S., Davies, S., Flammer, M., Russ, C., & Hughes, J. (2010) · Drug Safety · doi:10.2165/11319180-000000000-00000 · Cited by 142
Kasliwal, R., Wilton, L. V., & Shakir, S. A. W. (2009) · Drug Safety · doi:10.2165/00002018-200932060-00006 · Cited by 71
Varenicline Withdrawal-Induced Delirium With Psychosis
MAY, A. C., & Rose, D. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09081194 · Cited by 38
Coulter, D. M. (2002) · doi:10.1002/0470853093.ch27 · Cited by 32
Research works printed but not linked: 4
- Elijah, 2010 Aug, Aust Prescrib, 33, 120
- Kunac, 2008 Oct 3, N Z Med J, 121, 76
- Karch, 1975 Dec 22, JAMA, 234, 1236, 10.1001/jama.234.12.1236 · doi:10.1001/jama.234.12.1236 · Paper page
- 2009, FDA Drug Saf Newsletter, 2, 1
Cited by
Pharmacological interventions for smoking cessation: an overview and network meta-analysis
Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009329.pub2 · Cited by 1,243
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Interventions for smoking cessation and reduction in individuals with schizophrenia
Tsoi, D. T., Porwal, M., & Webster, A. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007253.pub3 · Cited by 304
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub6 · Cited by 177
Metadata
- Authors
- Harrison-Woolrych, M., & Ashton, J.
- Affiliations
- University of Otago (NZ)
- Venue
- Drug Safety
- Published
- 2011-09
- Volume
- 34
- Issue
- 9
- Pages
- 763-772
- ISSN
- 0114-5916 (ISSN-L)
- OpenAlex
- W14210466
- Cited by
- 54
- References
- 17
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 2 · 2021: 1 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 6 · 2013: 8 · 2012: 7
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Keywords
- varenicline, psychiatric adverse events, depression, suicidal ideation, psychosis, self-harm, insomnia, sleep disorders, withdrawal reactions, smoking cessation, post-marketing surveillance, prescription-event monitoring, New Zealand patients, occurrence rate, data linkage, suicide
- MeSH terms
- Varenicline, Adult, Aged, Aged, 80 and over, Mental Disorders, Benzazepines, Female, Follow-Up Studies, Humans, Male, Middle Aged, New Zealand, Product Surveillance, Postmarketing, Prospective Studies, Surveys and Questionnaires, Quinoxalines, Sleep Wake Disorders, Cohort Studies, Smoking Cessation, Nicotinic Agonists, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychiatric Adverse Events Associated with Varenicline: An Intensive Postmarketing Prospective Cohort Study in New Zealand. https://app.cochat.ai/papers/10.2165/11594450-000000000-00000
- The paper
- Harrison-Woolrych, M., & Ashton, J. (2011). Psychiatric Adverse Events Associated with Varenicline: An Intensive Postmarketing Prospective Cohort Study in New Zealand. Drug Safety. https://doi.org/10.2165/11594450-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.